JP2019023645A5 - - Google Patents

Download PDF

Info

Publication number
JP2019023645A5
JP2019023645A5 JP2018169294A JP2018169294A JP2019023645A5 JP 2019023645 A5 JP2019023645 A5 JP 2019023645A5 JP 2018169294 A JP2018169294 A JP 2018169294A JP 2018169294 A JP2018169294 A JP 2018169294A JP 2019023645 A5 JP2019023645 A5 JP 2019023645A5
Authority
JP
Japan
Prior art keywords
polypeptide
seq
assay
biological sample
ros
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018169294A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019023645A (ja
JP6619070B2 (ja
Filing date
Publication date
Priority claimed from US13/113,676 external-priority patent/US20120208824A1/en
Application filed filed Critical
Publication of JP2019023645A publication Critical patent/JP2019023645A/ja
Publication of JP2019023645A5 publication Critical patent/JP2019023645A5/ja
Application granted granted Critical
Publication of JP6619070B2 publication Critical patent/JP6619070B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018169294A 2011-05-23 2018-09-11 肺癌におけるｒｏｓキナーゼ Active JP6619070B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/113,676 2011-05-23
US13/113,676 US20120208824A1 (en) 2006-01-20 2011-05-23 ROS Kinase in Lung Cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017173626A Division JP6404423B2 (ja) 2011-05-23 2017-09-11 肺癌におけるｒｏｓキナーゼ

Publications (3)

Publication Number Publication Date
JP2019023645A JP2019023645A (ja) 2019-02-14
JP2019023645A5 true JP2019023645A5 (cg-RX-API-DMAC7.html) 2019-05-09
JP6619070B2 JP6619070B2 (ja) 2019-12-11

Family

ID=46208827

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014512072A Active JP6210977B2 (ja) 2011-05-23 2012-05-23 肺癌におけるｒｏｓキナーゼ
JP2017173626A Active JP6404423B2 (ja) 2011-05-23 2017-09-11 肺癌におけるｒｏｓキナーゼ
JP2018169294A Active JP6619070B2 (ja) 2011-05-23 2018-09-11 肺癌におけるｒｏｓキナーゼ

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2014512072A Active JP6210977B2 (ja) 2011-05-23 2012-05-23 肺癌におけるｒｏｓキナーゼ
JP2017173626A Active JP6404423B2 (ja) 2011-05-23 2017-09-11 肺癌におけるｒｏｓキナーゼ

Country Status (13)

Country Link
US (3) US20120208824A1 (cg-RX-API-DMAC7.html)
EP (3) EP2715365B1 (cg-RX-API-DMAC7.html)
JP (3) JP6210977B2 (cg-RX-API-DMAC7.html)
KR (1) KR102123963B1 (cg-RX-API-DMAC7.html)
CN (2) CN106148525B (cg-RX-API-DMAC7.html)
CA (2) CA3020650C (cg-RX-API-DMAC7.html)
DK (2) DK3182128T3 (cg-RX-API-DMAC7.html)
ES (2) ES2611281T3 (cg-RX-API-DMAC7.html)
HU (1) HUE041780T2 (cg-RX-API-DMAC7.html)
PT (1) PT3182128T (cg-RX-API-DMAC7.html)
SI (1) SI3182128T1 (cg-RX-API-DMAC7.html)
TR (1) TR201902690T4 (cg-RX-API-DMAC7.html)
WO (1) WO2012162373A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
EP2881402B1 (en) 2009-02-12 2017-05-10 Cell Signaling Technology, Inc. Mutant ROS expression in human liver cancer
KR20180080342A (ko) * 2013-03-15 2018-07-11 익스프레션 패톨로지, 인크. 암 요법을 지시하는 srm 검정
AU2015203904B2 (en) * 2014-01-06 2018-07-19 Expression Pathology, Inc. SRM assay for PD-L1
WO2017153932A1 (en) 2016-03-10 2017-09-14 Novartis Ag Strn-alk fusion as a therapeutic target in gastric cancer
WO2017175111A1 (en) 2016-04-04 2017-10-12 Novartis Ag Strn-alk fusion as a therapeutic target in colorectal cancer
EP3592338A1 (en) * 2017-03-08 2020-01-15 ARIAD Pharmaceuticals, Inc. Pharmaceutical formulations comprising 5-chloro-n4
KR101987065B1 (ko) 2017-08-07 2019-06-10 주식회사 싸이토젠 Eml4-alk유전자 변이 분석방법
KR102167739B1 (ko) 2018-10-31 2020-10-19 한국과학기술연구원 Alk 또는 ros-1 인산화 효소 억제제 스크리닝을 위한 방법, 조성물 및 키트 및 방법
JP7313033B2 (ja) * 2019-03-01 2023-07-24 国立大学法人北海道大学 Ｉｋｚｆ１遺伝子変異を検出するための核酸プローブセット及び当該プローブセットを用いたｉｋｚｆ１遺伝子変異の検出方法
CN110632318B (zh) * 2019-10-28 2023-04-07 四川大学华西医院 Tpm3自身抗体检测试剂在制备肺癌筛查试剂盒中的用途
CN111440241B (zh) * 2020-05-31 2021-01-05 广东赛尔生物科技有限公司 一种包含特异性结合ros1的单克隆抗体的癌症检测试剂盒

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3023787A1 (de) 1980-06-25 1982-01-21 Studiengesellschaft Kohle mbH, 4330 Mülheim Verfahren zur erhoehung der inkorporation und der expression von genetischem material in die kerne von intakten zellen mit hilfe von liposomen
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4659678A (en) 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4727022A (en) 1984-03-14 1988-02-23 Syntex (U.S.A.) Inc. Methods for modulating ligand-receptor interactions and their application
EP0190205B1 (en) 1984-07-24 1992-10-21 Coselco Mimotopes Pty. Ltd. Method for determining mimotopes
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5756696A (en) 1986-01-16 1998-05-26 Regents Of The University Of California Compositions for chromosome-specific staining
US5447841A (en) 1986-01-16 1995-09-05 The Regents Of The Univ. Of California Methods for chromosome-specific staining
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
JP3056782B2 (ja) 1989-11-03 2000-06-26 ヴァンダービルト ユニバーシティ 標的器官内での遺伝子の発現用医薬組成物
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE4002897A1 (de) 1990-02-01 1991-08-08 Behringwerke Ag Herstellung und verwendung von genbanken synthetischer menschlicher antikoerper ("synthetische human-antikoerper-bibliotheken")
EP1566442B1 (de) 1990-02-01 2009-11-25 Siemens Healthcare Diagnostics Products GmbH Herstellung und Verwendung von Genbanken menschlicher Antikörper("Human-Antikörper-Bibliotheken")
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5491224A (en) 1990-09-20 1996-02-13 Bittner; Michael L. Direct label transaminated DNA probe compositions for chromosome identification and methods for their manufacture
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US6027725A (en) 1991-11-25 2000-02-22 Enzon, Inc. Multivalent antigen-binding proteins
JPH07509133A (ja) 1992-07-17 1995-10-12 リボザイム・ファーマシューティカルズ・インコーポレイテッド 動物疾患の処置のための方法および剤
US6710174B2 (en) 2001-09-13 2004-03-23 Isis Pharmaceuticals, Inc. Antisense inhibition of vascular endothelial growth factor receptor-1 expression
IL108367A0 (en) 1993-01-27 1994-04-12 Hektoen Inst For Medical Resea Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells
US6340674B1 (en) 1993-03-26 2002-01-22 Thomas Jefferson University Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides
US5480971A (en) 1993-06-17 1996-01-02 Houghten Pharmaceuticals, Inc. Peralkylated oligopeptide mixtures
US5529925A (en) 1993-12-03 1996-06-25 St. Jude Children's Research Hospital Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma
DE69534347T2 (de) 1994-01-31 2006-05-24 Trustees Of Boston University, Boston Bibliotheken aus Polyklonalen Antikörpern
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5783683A (en) 1995-01-10 1998-07-21 Genta Inc. Antisense oligonucleotides which reduce expression of the FGFRI gene
US5675063A (en) 1995-02-28 1997-10-07 Loyola University Of Chicago Immortalized rabbit hybridoma fusion partner
DK1143006T3 (da) 1995-08-18 2008-07-14 Morphosys Ip Gmbh Vektorer/DNA-sekvenser fra humane kombinatoriske antistofbiblioteker
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
US6617162B2 (en) 2001-12-18 2003-09-09 Isis Pharmaceuticals, Inc. Antisense modulation of estrogen receptor alpha expression
JP2003528024A (ja) 1997-12-16 2003-09-24 バレンティス・インコーポレーテッド 製剤化された核酸分子の無針注入
US7300753B2 (en) 1998-09-04 2007-11-27 John Rush Immunoaffinity isolation of modified peptides from complex mixtures
US7198896B2 (en) 1998-09-04 2007-04-03 Cell Signaling Technology, Inc. Immunoaffinity isolation of modified peptides from complex mixtures
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
WO2000053722A2 (en) 1999-03-10 2000-09-14 Phogen Limited Delivery of nucleic acids and proteins to cells
US7662793B2 (en) 1999-06-18 2010-02-16 University Of Pittsburgh Of The Commonwealth System Of Higher Education Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from a Pol III promoter
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
AU2001249622B2 (en) 2000-03-30 2007-06-07 Massachusetts Institute Of Technology RNA sequence-specific mediators of RNA interference
EP1315829B1 (en) 2000-09-09 2010-07-28 The Research Foundation Of State University Of New York Method and compositions for isolating metastatic cancer cells, and use in measuring metastatic potential of a cancer thereof
EP1873259B1 (en) 2000-12-01 2012-01-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. RNA interference mediated by 21 and 22nt RNAs
ES2344592T3 (es) 2001-01-05 2010-09-01 Pfizer Inc. Anticuerpos frente al receptor del factor de crecimiento similar a la insulina i.
JP2005514002A (ja) 2001-05-17 2005-05-19 ザ パブリック ヘルス リサーチ インスティテュート オブ ザ シティ オブ ニューヨーク，インコーポレーテッド Ｒｎａをアンチセンス攻撃するための標的部位の選択
US20040209832A1 (en) 2001-11-30 2004-10-21 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20030170891A1 (en) 2001-06-06 2003-09-11 Mcswiggen James A. RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA)
IL159177A0 (en) 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
WO2003016861A2 (en) 2001-08-14 2003-02-27 President And Fellows Of Harvard College Absolute quantification of proteins and modified forms thereof by multistage mass spectrometry
US20030219839A1 (en) 2001-09-20 2003-11-27 Katherine Bowdish Anti-PDGF antibodies and methods for producing engineered antibodies
US6734017B2 (en) 2001-09-28 2004-05-11 Isis Pharmaceuticals, Inc. Antisense modulation of vascular endothelial growth factor receptor-2 expression
DE10230997A1 (de) 2001-10-26 2003-07-17 Ribopharma Ag Medikament zur Erhöhung der Wirksamkeit eines Rezeptor-vermittelt Apoptose in Tumorzellen auslösenden Arzneimittels
JP2006508899A (ja) 2002-05-20 2006-03-16 アブジエニツクス・インコーポレイテツド ＥＧＦｒに対する抗体を使用する腎癌の治療方法
PT1523496E (pt) 2002-07-18 2011-09-29 Merus B V Produção de misturas de anticorpos de forma recombinante
US20040023390A1 (en) 2002-08-05 2004-02-05 Davidson Beverly L. SiRNA-mediated gene silencing with viral vectors
CN1854313B (zh) * 2002-09-30 2010-10-20 肿瘤疗法科学股份有限公司 非小细胞肺癌的诊断方法
US20050181375A1 (en) 2003-01-10 2005-08-18 Natasha Aziz Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
EP1603948A1 (en) 2003-03-14 2005-12-14 Pharmacia Corporation Antibodies to igf-i receptor for the treatment of cancers
US20050214301A1 (en) 2004-03-24 2005-09-29 Cell Signaling Technology, Inc. Antibodies specific for BCR-ABL fusion protein and uses thereof
NZ568654A (en) 2005-12-05 2012-02-24 Pfizer Prod Inc Method of treating abnormal cell growth
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
US8383799B2 (en) 2006-01-20 2013-02-26 Cell Signaling Technology, Inc. Translocation and mutant ROS kinase in human non-small cell lung carcinoma
ES2539830T3 (es) 2006-01-20 2015-07-06 Cell Signaling Technology, Inc. ROS quinasa mutante y de translocación en el carcinoma pulmonar no microcítico humano
US20100143918A1 (en) 2007-01-19 2010-06-10 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
DK2016089T3 (da) * 2006-04-14 2014-04-22 Cell Signaling Technology Inc Gendefekter og mutant-alk-kinase i humane faste tumorer
EP2447360A1 (en) 2006-04-14 2012-05-02 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
CA2598893C (en) 2006-10-11 2012-04-10 Astellas Pharma Inc. Eml4-alk fusion gene
JP2010511382A (ja) 2006-12-01 2010-04-15 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 癌関連タンパク質キナーゼ
US9096855B2 (en) * 2007-10-18 2015-08-04 Cell Signaling Technology, Inc. Translocation and mutant ROS kinase in human non-small cell lung carcinoma
AU2009215168A1 (en) 2008-02-12 2009-08-20 Dana-Farber Cancer Institute Fish assay for EML4 and ALK fusion in lung cancer
EP2881402B1 (en) * 2009-02-12 2017-05-10 Cell Signaling Technology, Inc. Mutant ROS expression in human liver cancer
GB2467901A (en) 2009-02-12 2010-08-18 Norgine Bv 3',6'-dihydroxy-5(6)-nitrospiro[2-benzofuran-3,9'-xanthene]-1-one mixt. by reacting 4-nitrophthalic acid/anhydride & benzene-1,3-diol in methanesulphonic acid
WO2010128659A1 (ja) * 2009-05-08 2010-11-11 アステラス製薬株式会社 ジアミノへテロ環カルボキサミド化合物
US20130288240A1 (en) * 2010-05-21 2013-10-31 Cell Signaling Technology, Inc. Alk and ros kinase in cancer

Similar Documents

Publication Publication Date Title
JP2019023645A5 (cg-RX-API-DMAC7.html)
Hoffmann et al. HPV DNA, E6* I-mRNA expression and p16INK4A immunohistochemistry in head and neck cancer–how valid is p16INK4A as surrogate marker?
JP2017108751A5 (cg-RX-API-DMAC7.html)
ES2538362T3 (es) Clasificación, estadificación y pronóstico del cáncer mediante el uso de osteopontina-C
CN107541563B (zh) 一种用于早期诊断、预测脓毒血症并发急性肾损伤的分子标记物、试剂盒及应用
JP2009039107A5 (cg-RX-API-DMAC7.html)
KR102180117B1 (ko) 간암 특이적 바이오 마커
JP2009502116A5 (cg-RX-API-DMAC7.html)
JP2008506407A5 (cg-RX-API-DMAC7.html)
JP2018516533A5 (cg-RX-API-DMAC7.html)
JP2011517937A5 (cg-RX-API-DMAC7.html)
EP2051809A1 (en) Analyte manipulation and detection
Sinha et al. Pro-oncogenic, intra host viral quasispecies in Diffuse large B cell lymphoma patients with occult Hepatitis B Virus infection
Zou et al. Heterozygote of TAP1 Codon637 decreases susceptibility to HPV infection but increases susceptibility to esophageal cancer among the Kazakh populations
KR20220078659A (ko) 생물학적 샘플 및 rna 안정화를 위한 조성물, 방법 및 키트
JP2012507291A5 (cg-RX-API-DMAC7.html)
CN104694666A (zh) 一种检测乙肝病毒联合变异预测肝癌发生的试剂盒
WO2017033905A1 (ja) Ｏｃｌｎ－ａｒｈｇａｐ２６遺伝子の検出方法
KR101670135B1 (ko) 리포칼린 2 단백질에 특이적으로 결합하는 dna 앱타머 및 이의 용도
JP2010187665A (ja) オキサ型β−ラクタマーゼ産生菌の検出方法、同定方法及びキット
WO2018107930A1 (zh) 外周血循环肿瘤细胞检测体系及其应用
KR101418836B1 (ko) 간질환 진단용 마커 및 이의 용도
CN109266653B (zh) 一种耐药异质性循环肿瘤细胞捕获与基因分析的试剂、装置和方法
Huang et al. Nasopharyngeal extranodal NK/T-cell lymphoma, nasal type: retrospective study of 18 consecutive cases in Guangzhou, China
US20080108070A1 (en) Methods, compositions, and kits for the detection and monitoring of colon cancer